Somatotropin Deficiency Market Report Highlights
The companies and academics are working to assess challengesand seek opportunities that could influence Somatotropin Deficiency R&D.The therapies under development are focused on novel approaches to treat/improve Somatotropin Deficiency.
Somatotropin Deficiency Emerging Drugs Chapters
This segment of the Somatotropin Deficiency report enclosesits detailed analysis of various drugs in different stages of clinicaldevelopment, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Do you know about Somatotropin Deficiency Market Share?
Somatotropin Deficiency Emerging Drugs
Ethansomatropin (GX-H9): Genexine
Genexine’s drug candidate, Ethansomatropin (GX-H9), is aclass of recombinant somatropin fusion protein molecule in phase III for thetreatment of Somatotropin Deficiency. The drug stimulates the production of insulin-like growth factor-1 in the liver, which has growth-stimulating effects on various tissues and increases the activities of osteoclast, and chondrocytes tissues thus stimulating bone growth.
Ibutamoren (LUM-201): Lumos Pharma
Lumos Pharma’s “breakthrough” drug Ibutamoren (LUM-201) iscurrently being evaluated for the treatment of Somatotropin Deficiency and hasdemonstrated good safety and efficacy profile in phase II trials. Ibutamoren is an orphan drug and is a growth hormone releasing factor agonists.
Somatotropin Deficiency: Therapeutic Assessment
- This segment of the report provides insights about thedifferent Somatotropin Deficiency drugs segregated based on followingparameters that define the scope of the report, such as:
Major Players in Somatotropin Deficiency
- There are approx. 10+ key companies which are developing thetherapies for Somatotropin Deficiency. The companies which have theirSomatotropin Deficiency drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Genexine and others.
Phases
- DelveInsight’s report covers around 10+ products underdifferent phases of clinical development like
Late-stage products (Phase III)
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
To know more information about Somatotropin Deficiency Market Size
Recommended Blogs-
-
What are the Somatotropin Deficiency Market Report Highlights and Emerging Drugs?
-
What is Somatotropin Deficiency Market Report and Drugs?
-
About Somatotropin Deficiency Market Insights Report Information
-
Know about Somatotropin Deficiency Market Insights Report Details
